Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 218 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Lewy Body Parkinson Disease Clear all

Completed Phase 1Phase 2 Interventional

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

NCT04700072

View directory record Official record

Conditions: Melanoma
Interventions: Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years

Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more

Source: ClinicalTrials.gov public record

Updated Oct 27, 2025 · Synced May 22, 2026, 12:44 AM EDT

Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877

View directory record Official record

Conditions: Endometrial Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more

Source: ClinicalTrials.gov public record

Updated Jun 8, 2025 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

NCT03976375

View directory record Official record

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 28
States / cities: Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more

Source: ClinicalTrials.gov public record

Updated Aug 14, 2025 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 3 Interventional Results available

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

NCT03867084

View directory record Official record

Conditions: Hepatocellular Carcinoma
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 24
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more

Source: ClinicalTrials.gov public record

Updated Apr 23, 2026 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 1 Interventional Results available

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914

View directory record Official record

Conditions: Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions: INCB001158, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more

Source: ClinicalTrials.gov public record

Updated Aug 4, 2025 · Synced May 22, 2026, 12:44 AM EDT

Completed No phase listed Observational Accepts healthy volunteers

Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

NCT00058721

View directory record Official record

Conditions: Parkinson Disease
Interventions: I-123-5-IA85380; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed

Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 3, 2008 · Synced May 22, 2026, 12:44 AM EDT

Completed No phase listed Observational

Gene Analysis of Parkinson's Disease

NCT00001643

View directory record Official record

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older

Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 1, 2017 · Synced May 22, 2026, 12:44 AM EDT

Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115

View directory record Official record

Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions: pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 19
States / cities: Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 3 Interventional Results available

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472

View directory record Official record

Conditions: Head and Neck Cancer
Interventions: Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 14
States / cities: Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more

Source: ClinicalTrials.gov public record

Updated Dec 2, 2025 · Synced May 22, 2026, 12:44 AM EDT

Recruiting No phase listed Observational

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection; Diagnostic Test · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 1,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

NCT03834519

View directory record Official record

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 29
States / cities: Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more

Source: ClinicalTrials.gov public record

Updated May 17, 2025 · Synced May 22, 2026, 12:44 AM EDT

Active, not recruiting Phase 3 Interventional

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728

View directory record Official record

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Pembrolizumab, Placebo; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 22, 2026, 12:44 AM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334

View directory record Official record

Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Source: ClinicalTrials.gov public record

Updated Feb 17, 2026 · Synced May 22, 2026, 12:44 AM EDT

Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817

View directory record Official record

Conditions: Small Cell Lung Carcinoma
Interventions: coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556

View directory record Official record

Conditions: Dementia-related Psychosis
Interventions: Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 50 Years to 90 Years

Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 27
States / cities: Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more

Source: ClinicalTrials.gov public record

Updated Jun 20, 2021 · Synced May 22, 2026, 12:44 AM EDT

Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358

View directory record Official record

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Source: ClinicalTrials.gov public record

Updated Mar 10, 2026 · Synced May 22, 2026, 12:44 AM EDT

Completed No phase listed Observational

Synuclein-One Study

NCT04700722

View directory record Official record

Conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
Interventions: Skin Biopsy; Diagnostic Test
Lead sponsor: CND Life Sciences; Other
Eligibility: 40 Years to 99 Years

Enrollment: 428 participants
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Source: ClinicalTrials.gov public record

Updated Jan 2, 2024 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 1 Interventional Results available

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

NCT03396445

View directory record Official record

Conditions: Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
Interventions: Boserolimab, Pembrolizumab, Pemetrexed, Carboplatin, Nab-paclitaxel; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Mobile, Alabama • Sarasota, Florida • Germantown, Tennessee

Source: ClinicalTrials.gov public record

Updated Nov 4, 2025 · Synced May 22, 2026, 12:44 AM EDT

Completed Not applicable Interventional

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

NCT03076671

View directory record Official record

Conditions: Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions: Palliative Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 105 Years

Enrollment: 783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Source: ClinicalTrials.gov public record

Updated May 13, 2021 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 4 Interventional Results available

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

NCT04489888

View directory record Official record

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Pembrolizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: New Haven, Connecticut • Newark, Delaware • Jacksonville, Florida + 11 more

Source: ClinicalTrials.gov public record

Updated Jun 18, 2025 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

NCT04662710

View directory record Official record

Conditions: Advanced/Metastatic Gastroesophageal Adenocarcinoma
Interventions: Pembrolizumab, Lenvatinib, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Louisville, Kentucky + 8 more

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 22, 2026, 12:44 AM EDT

Completed No phase listed Observational

Speech Accessibility Project

NCT05889260

View directory record Official record

Conditions: Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions: Not listed
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older

Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Denver, Colorado • Urbana, Illinois

Source: ClinicalTrials.gov public record

Updated Aug 16, 2025 · Synced May 22, 2026, 12:44 AM EDT

Withdrawn Not applicable Interventional

Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

NCT00907595

View directory record Official record

Conditions: Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders, Circadian Dysregulation
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 90 Years

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Nov 5, 2012 · Synced May 22, 2026, 12:44 AM EDT

Completed Phase 1 Interventional

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

NCT03666273

View directory record Official record

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions: Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more

Source: ClinicalTrials.gov public record

Updated May 27, 2024 · Synced May 22, 2026, 12:44 AM EDT